Evidence grade: MODERATE — Supported by moderate evidence.
PET could resolve the pseudoprogression problem, but adoption is limited by access and single-center heterogeneous evidence.
PET-RANO/working-group support is largely built on retrospective, heterogeneous-threshold single-center data; outcome-linked prospective evidence is sparse.
Prospective randomized/pragmatic trial: MRI±amino-acid PET for progression assessment with management-change and outcome endpoints; harmonized SUV/TBR thresholds.
This is an educational research resource from Resonant Labs, not clinical advice. Evidence grades and controversies are summarized from the literature and may change as the field evolves.